These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35737227)

  • 1. Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018.
    Liu Y; Skup M; Yang M; Qi CZ; Wu EQ
    Adv Ther; 2022 Aug; 39(8):3711-3734. PubMed ID: 35737227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.
    Hillhouse E; Mathurin K; Bibeau J; Parison D; Rahal Y; Lachaine J; Beauchemin C
    Adv Ther; 2022 Jan; 39(1):455-487. PubMed ID: 34780028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study.
    Hellström PM; Gemmen E; Ward HA; Koo H; Faccin F; Xue Z; Malmborg P
    Scand J Gastroenterol; 2022 Dec; 57(12):1435-1442. PubMed ID: 35833832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.
    Numan S; Faccin F
    Adv Ther; 2018 Sep; 35(9):1295-1332. PubMed ID: 30084060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.
    Fitzgerald T; Melsheimer R; Lafeuille MH; Lefebvre P; Morrison L; Woodruff K; Lin I; Emond B
    Biologics; 2021; 15():1-15. PubMed ID: 33442230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.
    Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL;
    Lancet Rheumatol; 2024 Jul; 6(7):e438-e446. PubMed ID: 38843858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.
    Liu Y; Yang M; Garg V; Wu EQ; Wang J; Skup M
    Adv Ther; 2019 Aug; 36(8):1851-1877. PubMed ID: 31168766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review.
    Bakalos G; Zintzaras E
    Clin Ther; 2019 Jan; 41(1):155-173.e13. PubMed ID: 30551802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    Sci Rep; 2022 Nov; 12(1):19569. PubMed ID: 36380105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
    Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
    Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
    Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and safety of anti-TNF biosimilars versus originators in immune-mediated inflammatory diseases: an observational study on the French National Health Data System.
    Jourdain H; Hoisnard L; Sbidian E; Zureik M
    RMD Open; 2024 Mar; 10(1):. PubMed ID: 38453213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Survival of Subcutaneous Biosimilar Tumor Necrosis Factor Inhibitors Compared to Originators: Results From a Multicenter Prospective Registry.
    Martínez-Vidal MP; Fernández-Carballido C; Otero-Varela L; Ruiz FJM; Pérez-Vera Y; Arija SM; Fernández CC; Jovaní V; Expósito L; Lario BÁ; García-González J; Sánchez-Alonso F; Castrejón I
    J Rheumatol; 2024 Sep; 51(9):877-883. PubMed ID: 38825358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
    Gisbert JP; Chaparro M
    Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time.
    Overbeek JA; Kuiper JG; Bakker M; van den Bemt BJFB; Herings RMC
    Br J Clin Pharmacol; 2022 Feb; 88(4):1804-1810. PubMed ID: 34571570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uptake of rheumatology biosimilars in the absence of forced switching.
    Di Giuseppe D; Frisell T; Ernestam S; Forsblad-D'Elia H; Lindqvist E; Lindström U; Sjöwall C; Askling J;
    Expert Opin Biol Ther; 2018 May; 18(5):499-504. PubMed ID: 29633865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.